Brief: Brickell Biotech Acquires Exclusive Global Rights To Portfolio Of Novel Sting Inhibitors

Carna Biosciences

02/02/2022 12:42

Feb 2 (Reuters) - Carna Biosciences Inc  4572.T :
    * BRICKELL BIOTECH ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO
PORTFOLIO
OF NOVEL STING INHIBITORS TARGETING AUTOIMMUNE AND INFLAMMATORY
DISEASES FROM CARNA BIOSCIENCES
    * BRICKELL BIOTECH-  CO & CARNA BIOSCIENCES ENTERED INTO A
LICENSING AGREEMENT
    * BRICKELL BIOTECH INC - UNDER TERMS OF LICENSE AGREEMENT,
BRICKELL WILL MAKE A ONE-TIME CASH PAYMENT TO CARNA OF $2.0
MILLION
    * BRICKELL BIOTECH INC - IN ADDITION, BRICKELL WILL PAY
CARNA
SUCCESS-BASED DEVELOPMENT, REGULATORY, AND SALES MILESTONE
PAYMENTS OF UP TO $258.0 MILLION
    * BRICKELL BIOTECH INC - CARNA IS ALSO ELIGIBLE TO RECEIVE
TIERED
ROYALTY PAYMENTS RANGING FROM MID-SINGLE DIGITS UP TO 10% OF NET
SALES
    * BRICKELL BIOTECH INC - BRICKELL WILL BE RESPONSIBLE FOR
ALL
FUTURE DEVELOPMENT ACTIVITIES AND EXPENSES RELATED TO STING
INHIBITOR PLATFORM

Source text for Eikon:  ID:nGNXbLC1bn 
Further company coverage:  4572.T 

 ((Reuters.Briefs@thomsonreuters.com;))